AR065850A1 - Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph - Google Patents
Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de phInfo
- Publication number
- AR065850A1 AR065850A1 ARP080101237A ARP080101237A AR065850A1 AR 065850 A1 AR065850 A1 AR 065850A1 AR P080101237 A ARP080101237 A AR P080101237A AR P080101237 A ARP080101237 A AR P080101237A AR 065850 A1 AR065850 A1 AR 065850A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- control agent
- solid pharmaceutical
- benzimidazol
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composicion farmacéutica solida que contiene el compuesto (1) el cual ejerce una accion antagonica del receptor de angiotensina II y un agente de control del pH. La composicion es superior en términos de la estabilidad y propiedad de disolucion delcompuesto (i) Reivindicacion 1: Una composicion farmacéutica solida caracterizada porque comprende un compuesto representado por la formula (i) en la cual R1 es un grupo heterocíclico que contiene nitrogeno monocíclico con un átomo de hidrogeno quepuede ser desprotonizado, R2 es un grupo carboxílico esterificado y R3 es un alquilo inferior opcionalmente sustituido, o una sal del mismo, y un agente de control del pH. Reivindicacion 2: La composicion farmacéutica de la Reivindicacion 1,caracterizada porque la sal del compuesto representado por la formula (I) es una sal de potasio de (5-metil-2-oxo-1,3-dioxol-4-il) metil 2-etoxi-1-{[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il]-1H-benzimidazol-7-carboxilato. Reivindicacion 4: La composicion farmacéutica de la Reivindicacion 3 caracterizada porque el agente de control del pH es un fumarato monosodico o una combinacion de ácido fumárico e hidroxido de sodio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90851507P | 2007-03-28 | 2007-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065850A1 true AR065850A1 (es) | 2009-07-08 |
Family
ID=39590787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101237A AR065850A1 (es) | 2007-03-28 | 2008-03-26 | Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph |
Country Status (19)
Country | Link |
---|---|
US (1) | US9066936B2 (es) |
EP (1) | EP2124903B1 (es) |
JP (1) | JP5283632B2 (es) |
KR (1) | KR20090125846A (es) |
CN (1) | CN101677961B (es) |
AR (1) | AR065850A1 (es) |
AU (1) | AU2008235790B2 (es) |
BR (1) | BRPI0809522A2 (es) |
CA (1) | CA2681143C (es) |
CL (1) | CL2008000868A1 (es) |
EA (1) | EA016593B1 (es) |
ES (1) | ES2743784T3 (es) |
IL (1) | IL201188A0 (es) |
MX (1) | MX2009010167A (es) |
NZ (1) | NZ579851A (es) |
PE (2) | PE20130210A1 (es) |
PT (1) | PT2124903T (es) |
TW (1) | TWI415634B (es) |
WO (1) | WO2008123536A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2732018C (en) | 2008-07-31 | 2017-07-04 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition |
AR073380A1 (es) * | 2008-09-25 | 2010-11-03 | Takeda Pharmaceutical | Composicion farmaceutica solida. comprimido multicapa |
CN103096878B (zh) * | 2011-05-23 | 2015-06-17 | 江苏恒瑞医药股份有限公司 | 包含苯并咪唑衍生物的固体药物组合物 |
CN102351853B (zh) * | 2011-08-29 | 2014-03-12 | 石药集团欧意药业有限公司 | 一种阿齐沙坦酯化合物、制备方法及其药物组合物 |
HUE032635T2 (en) | 2012-09-19 | 2017-10-30 | Taiho Pharmaceutical Co Ltd | For oral administration of pharmaceutical compositions having improved elution and / or absorbance |
EP2928468A4 (en) | 2012-12-05 | 2016-07-27 | Sawai Seiyaku Kk | PREPARATION CONTAINING CANDÉSARTAN CILEXÉTIL |
WO2014102628A1 (en) | 2012-12-31 | 2014-07-03 | Ranbaxy Laboratories Limited | Stable pharmaceutical composition comprising azilsartan medoxomil |
EP2952187A4 (en) | 2013-01-30 | 2016-08-17 | Sawai Seiyaku Kk | PHARMACEUTICAL COMPOSITION WITH CANDESARTAN CILEXETIL |
CN105079815A (zh) * | 2014-04-30 | 2015-11-25 | 广东东阳光药业有限公司 | 一种阿齐沙坦酯钾组合物及其制备方法 |
IN201721047406A (es) | 2017-12-30 | 2020-06-19 | Lupin Limited | |
IN202021028444A (es) * | 2020-07-03 | 2022-01-28 | ||
CN117122570B (zh) * | 2022-05-19 | 2024-04-09 | 北京阳光诺和药物研究股份有限公司 | 一种提高稳定性的美阿沙坦钾片及其制备方法 |
WO2024109927A1 (zh) * | 2022-11-24 | 2024-05-30 | 上海云晟研新生物科技有限公司 | 包含美阿沙坦钾与钙通道阻滞剂的药物组合物,及其制备方法及应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250554A (en) * | 1989-10-24 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives useful as angiotensin II inhibitors |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US6004989A (en) * | 1990-04-27 | 1999-12-21 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
TW284688B (es) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
US5605919A (en) * | 1993-02-26 | 1997-02-25 | Takeda Chemical Industries, Ltd. | Treatment for viral diseases |
CA2115985A1 (en) * | 1993-02-25 | 1994-08-26 | Kohei Nishikawa | Vascular hypertrophy suppressor |
JP3810020B2 (ja) * | 1993-04-22 | 2006-08-16 | 武田薬品工業株式会社 | 腎疾患の予防または治療剤 |
US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
CZ154994A3 (en) * | 1993-07-02 | 1995-09-13 | Senju Pharma Co | Visual hypotensive agent |
KR19990087076A (ko) * | 1996-04-05 | 1999-12-15 | 다께다 구니오 | 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물 |
IL137979A0 (en) * | 1998-03-04 | 2001-10-31 | Takeda Chemical Industries Ltd | Production, release preparation for aii antagonist-sustained and use thereof |
AU2573800A (en) * | 1999-02-19 | 2000-09-04 | Takeda Chemical Industries Ltd. | Percutaneous absorption preparations of compound having angiotensin ii receptor antagonism |
WO2000066161A1 (fr) * | 1999-04-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante |
DE60037192T2 (de) * | 1999-07-21 | 2008-05-15 | Takeda Pharmaceutical Co. Ltd. | Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens |
WO2001060362A1 (en) * | 2000-02-18 | 2001-08-23 | Takeda Chemical Industries, Ltd. | TNF-α INHIBITORS |
JP2001316296A (ja) * | 2000-02-21 | 2001-11-13 | Takeda Chem Ind Ltd | 水に難溶性の生理活性化合物の徐放性製剤、その製造法および用途 |
AU2001232348A1 (en) * | 2000-02-21 | 2001-08-27 | Takeda Chemical Industries Ltd. | Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same |
WO2003041739A1 (en) * | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Anticaner agents |
AU2002349673A1 (en) * | 2001-12-03 | 2003-06-17 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
JP4484427B2 (ja) * | 2001-12-03 | 2010-06-16 | 武田薬品工業株式会社 | インスリン抵抗性改善剤 |
KR101092279B1 (ko) * | 2002-12-27 | 2011-12-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 체중 증가 억제제 |
WO2004082679A1 (ja) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
WO2005117591A2 (en) * | 2004-05-28 | 2005-12-15 | Andrx Labs Llc | Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist |
US20080004320A1 (en) * | 2004-09-06 | 2008-01-03 | Kowa Co., Ltd. | Remedy for Glomerular Disease |
US20060159747A1 (en) | 2004-12-17 | 2006-07-20 | Boehringer Ingelheim International Gmbh | Telmisartan and hydrochlorothiazide combination therapy |
WO2006124713A2 (en) * | 2005-05-13 | 2006-11-23 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
US20080279942A1 (en) * | 2005-06-27 | 2008-11-13 | Takeshi Hamaura | Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker |
DE102005031577A1 (de) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
TWI494134B (zh) | 2006-06-20 | 2015-08-01 | Siegfried Generics Int Ag | 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法 |
WO2008045006A1 (en) * | 2006-10-11 | 2008-04-17 | Fako Ilaclari A. S. | Formulations of candesartan |
WO2008068217A2 (en) | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
US9387249B2 (en) * | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
-
2008
- 2008-03-26 AU AU2008235790A patent/AU2008235790B2/en not_active Ceased
- 2008-03-26 PE PE2012001692A patent/PE20130210A1/es not_active Application Discontinuation
- 2008-03-26 PT PT08739635T patent/PT2124903T/pt unknown
- 2008-03-26 CL CL200800868A patent/CL2008000868A1/es unknown
- 2008-03-26 NZ NZ579851A patent/NZ579851A/en not_active IP Right Cessation
- 2008-03-26 ES ES08739635T patent/ES2743784T3/es active Active
- 2008-03-26 CA CA2681143A patent/CA2681143C/en active Active
- 2008-03-26 PE PE2008000540A patent/PE20090550A1/es not_active Application Discontinuation
- 2008-03-26 JP JP2009541656A patent/JP5283632B2/ja active Active
- 2008-03-26 EA EA200970896A patent/EA016593B1/ru not_active IP Right Cessation
- 2008-03-26 US US12/450,403 patent/US9066936B2/en active Active
- 2008-03-26 TW TW097110689A patent/TWI415634B/zh not_active IP Right Cessation
- 2008-03-26 KR KR1020097022475A patent/KR20090125846A/ko not_active Application Discontinuation
- 2008-03-26 MX MX2009010167A patent/MX2009010167A/es active IP Right Grant
- 2008-03-26 BR BRPI0809522-1A2A patent/BRPI0809522A2/pt not_active IP Right Cessation
- 2008-03-26 AR ARP080101237A patent/AR065850A1/es not_active Application Discontinuation
- 2008-03-26 CN CN2008800177926A patent/CN101677961B/zh active Active
- 2008-03-26 EP EP08739635.4A patent/EP2124903B1/en active Active
- 2008-03-26 WO PCT/JP2008/056522 patent/WO2008123536A1/en active Application Filing
-
2009
- 2009-09-24 IL IL201188A patent/IL201188A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20090125846A (ko) | 2009-12-07 |
US9066936B2 (en) | 2015-06-30 |
PE20130210A1 (es) | 2013-03-11 |
US20100121071A1 (en) | 2010-05-13 |
EP2124903A1 (en) | 2009-12-02 |
TWI415634B (zh) | 2013-11-21 |
PT2124903T (pt) | 2019-09-26 |
WO2008123536A1 (en) | 2008-10-16 |
ES2743784T3 (es) | 2020-02-20 |
CA2681143A1 (en) | 2008-10-16 |
TW200902089A (en) | 2009-01-16 |
EA016593B1 (ru) | 2012-06-29 |
NZ579851A (en) | 2012-02-24 |
BRPI0809522A2 (pt) | 2014-10-14 |
JP2010522692A (ja) | 2010-07-08 |
JP5283632B2 (ja) | 2013-09-04 |
CL2008000868A1 (es) | 2008-10-10 |
MX2009010167A (es) | 2009-10-12 |
EA200970896A1 (ru) | 2010-04-30 |
AU2008235790A1 (en) | 2008-10-16 |
CA2681143C (en) | 2017-01-03 |
EP2124903B1 (en) | 2019-06-12 |
CN101677961A (zh) | 2010-03-24 |
IL201188A0 (en) | 2010-05-17 |
CN101677961B (zh) | 2012-10-17 |
PE20090550A1 (es) | 2009-06-01 |
AU2008235790B2 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065850A1 (es) | Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph | |
AR112118A2 (es) | Inhibidores de pi-3 quinasa | |
PE20081228A1 (es) | Compuesto heteromonociclico | |
AR073380A1 (es) | Composicion farmaceutica solida. comprimido multicapa | |
AR079550A1 (es) | Derivados de pirazol | |
NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
PE20081800A1 (es) | NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
TW200640879A (en) | Amide derivatives | |
AR063529A1 (es) | Compuestos de pirazolina | |
PE20140934A1 (es) | Derivados de pirazol | |
RS20080510A (en) | Benzimidazole derivative and use as angiotensin ii antagonist | |
PE20060729A1 (es) | Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina | |
PE20071337A1 (es) | Nanoparticulas que comprenden imatinib, composiciones farmaceuticas y dispositivos que comprenden dichas nanoparticulas y uso farmaceutico de las mismas | |
PE20120315A1 (es) | Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino | |
PE20141169A1 (es) | Derivados de etinilo | |
PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
CO6612226A2 (es) | Tableta | |
PE20071149A1 (es) | Derivados de benzimidazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |